HCV 基因型 1a 分为 1 型和 2 型以及 HIV 感染患者的基因型 1b 中 NS3 蛋白酶抑制剂天然耐药性的分布。
Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
机构信息
Department of Infectious Diseases, Scientific Institute Ospedale San Raffaele, Italy; Vita-Salute University, Milan, Italy.
Department of Infectious Diseases, Scientific Institute Ospedale San Raffaele, Italy.
出版信息
Clin Microbiol Infect. 2016 Apr;22(4):386.e1-386.e3. doi: 10.1016/j.cmi.2015.12.007. Epub 2015 Dec 17.
Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.
在 59 例 HIV/HCV 合并感染患者中，研究了丙型肝炎病毒 (HCV) 基因型 (G) 1a 蛋白酶结构域内的天然耐药相关变异 (RAV)，分为 1 组和 2 组和 G1b。在 23 例 G1a/1 组和 19 例 G1b 中检测到 RAV (p 0.0059)。G1a/2 组和 G1b 的 RAV 频率相似 (p 0.1672)。在两个 G1a/2 组和 1 个 G1b 序列中检测到对大环化合物西美普韦和帕利帕韦的交叉耐药，而在 G1a/1 序列中则没有。通过 NS3 结构域的群体分析同时对亚型和天然 RAV 进行特征分析，可能为包括蛋白酶抑制剂在内的抗 HCV 治疗策略增加重要信息。
Zotero 插件